News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
中外製藥(4519.JP)全日漲幅5.9% 減肥藥數據利好
中外製藥(4519.JP)今日(20日)股價收盤於8,844日圓，全日漲幅5.9%。公司已把肥胖症藥物Orforglipron的全球開發及銷售權授予美國禮來(LLY.US)，相關藥物亦已獲美國FDA批准銷售。禮來於上周四(16日)公布Orforglipron第三期臨床試驗結果，顯示其在主要心血管不良事件風險方面，相對胰島素甘精不屬劣效，並達成主要評估指標。消...
Reset
Send
The window will close in 5 seconds
中外製藥(4519.JP)全日漲幅5.9% 減肥藥數據利好
Close
Recommend
2
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

中外製藥(4519.JP)今日(20日)股價收盤於8,844日圓，全日漲幅5.9%。公司已把肥胖症藥物Orforglipron的全球開發及銷售權授予美國禮來(LLY.US)      ，相關藥物亦已獲美國FDA批准銷售。禮來於上周四(16日)公布Orforglipron第三期臨床試驗結果，顯示其在主要心血管不良事件風險方面，相對胰島素甘精不屬劣效，並達成主要評估指標。消息為相關授權資產前景增添利好線索。(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.